Categories: Technology

Nokia Corporations Financial Calendar for 2026

 | Source: Nokia Oyj

Nokia Corporation
Stock Exchange Release
1 December 2025 at 8:00 EET

Nokia Corporation’s Financial Calendar for 2026

Espoo, Finland – In this stock exchange release, Nokia provides its 2026 financial calendar, which includes the planned publication dates of its financial reports.

Planned publication dates for Nokia’s financial reports in 2026:

  • report for Q4 and full year 2025: 29 January 2026
  • interim report for Q1 2026: 23 April 2026
  • report for Q2 2026 and half year 2026: 23 July 2026
  • interim report for Q3 2026 and January–September 2026: 22 October 2026

Publication of Nokia in 2025 annual report

Nokia plans to publish its Nokia in 2025 annual report, which includes the review by the Board of Directors and the audited annual accounts, during the week starting on 2 March 2026.

Nokia’s Annual General Meeting

Nokia’s Annual General Meeting 2026 is planned to be held on 9 April 2026. 

About Nokia
Nokia is a global leader in connectivity for the AI era. With expertise across fixed, mobile, and transport networks, we’re advancing connectivity to secure a brighter world.

Inquiries:

Nokia
Communications
Phone: +358 10 448 4900
Email: press.services@nokia.com
Maria Vaismaa, Vice President, Global Media Relations 

Nokia
Investor Relations
Phone: +358 931 580 507 
Email: investor.relations@nokia.com

GlobeNews Wire

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

2 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

2 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

2 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

2 hours ago